Early Psychosis
12
5
6
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
Digital Strategies to Advance Help-Seeking Aim 1 and 2
Digital Strategies to Advance Help-Seeking - Aim 3
Effects of an Acceptance-based Medication Adherence Therapy for Recent-onset Psychosis
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
Perception and Integration of Sensory Information in the Early Stages of Psychosis
BRAVE Program to Improve Safety and Reduce Violence Risk in Early Psychosis
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
R33: Levetiracetam in Early Psychosis
Effect of a Peer-led Self-management Program for Recent-onset Psychosis
PSYCHE Cognitive Remediation & Social Recovery Study
Intervention to Improve Coping With Negative Emotions in Patients With Psychosis (Feel-Good-Study)
Decision-making and Decision Support Among Emerging Adults With First Episode Psychosis